Type O Negative Red Blood Cell Utilization: Preserving this Rare and Lifesaving Resource (Updated Course Release Date: 03/08/2018)
Type O negative blood – every hospital wants a supply on its shelves. But with a prevalence of only seven percent within the population, this valuable resource must be managed with care. Dr. Mair will discuss ways to best utilize lifesaving type O negative red blood cells.

Massive Transfusion Protocols: Current Practices and New Innovations for Managing Traumatic Hemorrhage (Release Date: 11/30/2018) Massive transfusion practices have changed considerably in the last several years from primarily laboratory-guided therapy to formula-driven protocols. In this program, the rationale for developing massive transfusion protocols will be reviewed. The evidence in the literature supporting and refuting the use of high ratios of plasma to red blood cells will also be discussed. Lastly, new ideas and products that should be considered for use in a massive transfusion protocol will be described. There are no participant prerequisites for this activity. The result of the PROPPR study was published in JAMA in 2015 (JAMA 2015; 313(5): 471-482). There were no significant differences in the primary outcomes of 24-hour and 30-day all-cause mortality between the 1:1:1 group and the 1:1:2 group. Death due to exsanguination was decreased in the 1:1:1 group and more patients in that group achieved hemostasis. No other safety differences between the two groups was noted.

Last modified: Wednesday, February 6, 2019, 03:42 PM